

БИМЕДИЦИНА ВА АМАЛИЁТ ЖУРНАЛИ

8 ЖИЛД, 4 СОН

ЖУРНАЛ БИМЕДИЦИНЫ И ПРАКТИКИ

ТОМ 8, НОМЕР 4

JOURNAL OF BIOMEDICINE AND PRACTICE

VOLUME 8, ISSUE 4



Бош муҳаррир:

Ризаев Жасур Алимжанович
тиббиёт фанлари доктори, профессор,
Самарқанд давлат тиббиёт университети ректори
ORCID ID: 0000-0001-5468-9403

Бош муҳаррир ўринбосари:

Зиядуллаев Шухрат Худайбердиевич
тиббиёт фанлари доктори, Самарқанд давлат тиббиёт
университети Илмий ишлар ва инновациялар бўйича
проректори, **ORCID ID:** 0000-0002-9309-3933

Масъул котиб:

Самиева Гулноза Утқуровна
тиббиёт фанлари доктори, доцент,
Самарқанд давлат тиббиёт университети
ORCID ID: 0000-0002-6142-7054

Нашр учун масъул:

Шаханова Шахноза Шавкатовна
PhD, Самарқанд давлат тиббиёт университети,
онкология кафедраси
ORCID ID: 0000-0003-0888-9150

ТАХРИРИЯТ КЕНГАШИ:

Арипова Тамара Уктамовна

*Иммунология ва инсон геномикаси институти директори –
тиббиёт фанлари доктори, профессор, Ўзбекистон
Республикаси Фанлар академияси академиги*

Jin Young Choi

*Сеул миллий университети Стоматология мактаби оғиз ва
юз-жағ жаррохлиги департаменти профессори, Жанубий
Кореянинг юз-жағ ва эстетик жаррохлик ассоциацияси
президенти*

Абдуллаева Наргиза Нурмаатовна

*тиббиёт фанлари доктори, профессор, Самарқанд
давлат тиббиёт университети проректори, 1-клиникаси бош
врачи. **ORCID ID:** 0000-0002-7529-4248*

Худоярова Дилдора Рахимовна

*тиббиёт фанлари доктори, доцент, Самарқанд давлат
тиббиёт университети №1-сон Акушерлик ва гинекология
кафедраси мудири
ORCID ID: 0000-0001-5770-2255*

Орипов Фирдавс Суръатович

*тиббиёт фанлари доктори, доцент, Самарқанд давлат
тиббиёт университети Гистология, цитология ва
эмбриология кафедраси мудири
ORCID ID: 0000-0002-0615-0144*

Мавлянов Фарход Шавкатович

*тиббиёт фанлари доктори, Самарқанд давлат тиббиёт
университети болалар жаррохлиги кафедраси доценти
ORCID ID: 0000-0003-2650-4445*

Акбаров Миршавкат Мирлоимович

*тиббиёт фанлари доктори, В.Ваҳидов номидаги
Республика ихтисослаштирилган жаррохлик маркази*

Саидов Садамир Аброрович

*тиббиёт фанлар доктори,
Тошкент фармацевтика институти
ORCID ID: 0000-0002-6616-5428*

Бабалжанов Ойбек Абдужаббарович

*тиббиёт фанлари доктори, Тошкент педиатрия
тиббиёт институти, Тери-таносил, болалар
тери-таносил касалликлари ва ОИТС
ORCID ID: 0000-0002-3022-916X*

Теребаев Билим Алдамуратович

*тиббиёт фанлари номзоди, доцент, Тошкент
педиатрия тиббиёт институти Факультет болалар
хирургия кафедраси. **ORCID ID:** 0000-0002-5409-4327*

Юлдашев Ботир Ахматович

*тиббиёт фанлари номзоди,
Самарқанд давлат тиббиёт университети
№2-сон Педиатрия, неонатология ва болалар
касаликлари пропедевтикаси кафедраси доценти.
ORCID ID: 0000-0003-2442-1523*

Ибрагимова Малика Худайбергеновна

*тиббиёт фанлари доктори, профессор
Тошкент давлат стоматология институти
ORCID ID: 0000-0002-9235-1742*

Рахимов Нодир Махамматкулович

*тиббиёт фанлари доктори, Самарқанд давлат
тиббиёт университети, онкология кафедраси доценти
ORCID ID: 0000-0001-5272-5503*

Саҳифаловчи: Хуршид Мирзахмедов

Контакт редакций журналлов. www.tadqiqot.uz

ООО Tadqiqot город Ташкент,
улица Амира Темура пр.1, дом-2.
Web: <http://www.tadqiqot.uz/>; E-mail: info@tadqiqot.uz
Тел: (+998-94) 404-0000

Editorial staff of the journals of www.tadqiqot.uz

Tadqiqot LLC The city of Tashkent,
Amir Temur Street pr.1, House 2.
Web: <http://www.tadqiqot.uz/>; E-mail: info@tadqiqot.uz
Phone: (+998-94) 404-0000

Главный редактор:

Ризаев Жасур Алимджанович
доктор медицинских наук, профессор, Ректор
Самаркандского государственного медицинского
университета, **ORCID ID:** 0000-0001-5468-9403

Заместитель главного редактора:

Зиядуллаев Шухрат Худайбердиевич
доктор медицинских наук, проректор по научной
работе и инновациям Самаркандского государственного
медицинского университета, **ORCID ID:** 0000-0002-9309-

Ответственный секретарь:

Самиева Гульноза Уткуровна
доктор медицинских наук, доцент Самаркандского
государственного медицинского университета.
ORCID ID: 0000-0002-6142-7054

Ответственный за публикацию:

Шаханова Шахноза Шавкатовна
PhD кафедры онкологии Самаркандского
государственного медицинского университета
ORCID ID: 0000-0003-0888-9150

РЕДАКЦИОННЫЙ КОЛЛЕГИЯ:

Арипова Тамара Уктамовна

директор Института иммунологии и геномики человека
доктор медицинских наук, профессор, академик АН РУз

Jin Young Choi

профессор департамента оральной и челюстно-лицевой
хирургии школы стоматологии Стоматологического
госпиталя Сеульского национального университета,
Президент Корейского общества челюстно-лицевой и
эстетической хирургии

Абдуллаева Наргиза Нурмаатовна

доктор медицинских наук, профессор, проректор
Самаркандского государственного медицинского
университета, **ORCID ID:** 0000-0002-7529-4248

Худоярова Дилдора Рахимовна

доктор медицинских наук, доцент, заведующая кафедрой
Акушерства и гинекологии №1 Самаркандского
государственного медицинского университета
ORCID ID: 0000-0001-5770-2255

Орипов Фирдавс Суръатович

доктор медицинских наук, доцент, заведующий кафедрой
Гистологии, цитологии и эмбриологии Самаркандского
государственного медицинского университета
ORCID ID: 0000-0002-0615-0144

Мавлянов Фарход Шавкатович

доктор медицинских наук, доцент кафедры Детской
хирургии Самаркандского государственного медицинского
университета, **ORCID ID:** 0000-0003-2650-4445

Акбаров Миршавкат Миролимович

доктор медицинских наук,
Республиканский специализированный центр
хирургии имени академика В.Вахидова

Саидов Саидмир Аброрович

доктор медицинских наук, Ташкентский
фармацевтический институт
ORCID ID: 0000-0002-6616-5428

Бабаджанов Ойбек Абдужаббарович

доктор медицинских наук, Ташкентский педиатрический
медицинский институт, кафедра Дерматовенерология, детская
дерматовенерология и СПИД, **ORCID ID:** 0000-0002-3022-916X

Теребаев Билим Алдамуратович

кандидат медицинских наук, доцент кафедры Факультетской
детской хирургии Ташкентского педиатрического
медицинского института.
ORCID ID: 0000-0002-5409-4327

Юлдашев Ботир Ахматович

кандидат медицинских наук, доцент кафедры Педиатрии,
неонатологии и протекции детских болезней №2
Самаркандского государственного медицинского университета
ORCID ID: 0000-0003-2442-1523

Ибрагимова Малика Худайбергеновна

доктор медицинских наук, профессор
Ташкентского государственного
стоматологического института
ORCID ID: 0000-0002-9235-1742

Рахимов Нодир Махамматкулович

доктор медицинских наук, доцент кафедры
онкологии Самаркандского государственного
медицинского университета
ORCID ID: 0000-0001-5272-5503

Верстка: Хуршид Мирзахмедов

Контакт редакций журналов. www.tadqiqot.uz
ООО Tadqiqot город Ташкент,
улица Амира Темура пр.1, дом-2.
Web: <http://www.tadqiqot.uz/>; E-mail: info@tadqiqot.uz
Тел: (+998-94) 404-0000

Editorial staff of the journals of www.tadqiqot.uz
Tadqiqot LLC The city of Tashkent,
Amir Temur Street pr.1, House 2.
Web: <http://www.tadqiqot.uz/>; E-mail: info@tadqiqot.uz
Phone: (+998-94) 404-0000

Chief Editor:

Rizaev Jasur Alimjanovich
MD, DSc, Professor of Dental Medicine,
Rector of the Samarkand State Medical University
ORCID ID: 0000-0001-5468-9403

Deputy Chief Editor:

Ziyadullaev Shukhrat Khudayberdievich
Doctor of Medical Sciences, Vice-Rector for scientific work
and Innovation, Samarkand State Medical University
ORCID ID: 0000-0002-9309-3933

Responsible secretary:

Samieva Gulnoza Utkurovna
doctor of Medical Sciences, Associate Professor,
Samarkand State Medical University
ORCID ID: 0000-0002-6142-7054

Responsible for publication:

Shakhanova Shakhnoza Shaykatovna
PhD Department of Oncology
Samarkand State medical university
ORCID ID: 0000-0003-0888-9150

EDITORIAL BOARD:

Aripova Tamara Uktamovna

*Director of the Institute of Immunology and Human Genomics -
Doctor of Medical Sciences, Professor, Academician of the
Academy of Sciences of the Republic of Uzbekistan*

Jin Young Choi

*Professor Department of Oral and Maxillofacial
Surgery School of Dentistry Dental Hospital
Seoul National University, President of the
Korean Society of Maxillofacial Aesthetic Surgery*

Abdullaeva Nargiza Nurmatovna

*Doctor of Medical Sciences, Professor, Vice-Rector
Samarkand State Medical University, Chief Physician of
the 1st Clinic **ORCID ID:** 0000-0002-7529-4248*

Khudoyarova Dildora Rakhimovna

*Doctor of Medical Sciences, Associate Professor,
Head of the Department of Obstetrics and Gynecology,
Samarkand State Medical University No.1
ORCID ID: 0000-0001-5770-2255*

Oripov Firdavs Suratovich

*Doctor of Medical Sciences, Associate Professor,
Head of the Department of Histology, Cytology and
Embryology of Samarkand State Medical University.
ORCID ID: 0000-0002-0615-0144*

Mavlyanov Farkhod Shavkatovich

*Doctor of Medicine, Associate Professor of Pediatric
Surgery, Samarkand State Medical University
ORCID ID: 0000-0003-2650-4445*

Akbarov Mirshavkat Mirolimovich

*Doctor of Medical Sciences,
Republican Specialized Center of Surgery
named after academician V.Vakhidov*

Saidov Saidamir

*Doctor of Medical Sciences,
Tashkent Pharmaceutical Institute,
ORCID ID: 0000-0002-6616-5428*

Babadjanov Oybek Abdujabbarovich

*Doctor of sciences in medicine, Tashkent Pediatric
Medical Institute, Department of Dermatovenerology,
pediatric dermatovenerology and AIDS
ORCID ID: 0000-0002-3022-916X*

Terebaev Bilim Aldamuratovich

*Candidate of Medical Sciences, Associate Professor,
Tashkent Pediatric Medical Institute,
Faculty of Children Department of Surgery.
ORCID ID: 0000-0002-5409-4327.*

Yuldashev Botir Akhmatovich

*Candidate of Medical Sciences, Associate Professor of
Pediatrics, Neonatology and Propaedeutics of Pediatrics,
Samarkand State Medical University No. 2.
ORCID ID: 0000-0003-2442-1523*

Ibragimova Malika Xudayberganova

*Doctor of Medical Sciences, Professor,
Tashkent State Dental Institute
ORCID ID: 0000-0002-9235-1742*

Rahimov Nodir Maxammatkulovich

*DSc, Associate Professor of Oncology,
Samarkand State Medical University
ORCID ID: 0000-0001-5272-5503*

Page Maker: Khurshid Mirzakhmedov

Контакт редакций журналов. www.tadqiqot.uz
ООО Tadqiqot город Ташкент,
улица Амира Темура пр.1, дом-2.
Web: <http://www.tadqiqot.uz/>; E-mail: info@tadqiqot.uz
Тел: (+998-94) 404-0000

Editorial staff of the journals of www.tadqiqot.uz
Tadqiqot LLC The city of Tashkent,
Amir Temur Street pr.1, House 2.
Web: <http://www.tadqiqot.uz/>; E-mail: info@tadqiqot.uz
Phone: (+998-94) 404-0000

МУНДАРИЖА | СОДЕРЖАНИЕ | CONTENT

OBSTETRICS AND GYNECOLOGY

1. **An V. Andrey, Sharipova Kh. Feruza**
THE CLINICAL COURSE OF FOCAL MYOCARDITIS IN PREGNANT.....10
2. **Kamalova I. Malika, Askarova K. Fatima**
UTERINE MUCOSAL MORPHOLOGY OF INTRAUTERINE CONTRACEPTIVE USE
(LITERATURE REVIEW).....15
3. **Nasimova R. Nigina**
THE ROLE OF ESTROGENIC DEFICIENCY IN THE DEVELOPMENT AND
PROGRESSION OF GENITAL PROLAPSE.....20

HEMATOLOGY

4. **Kayumov A. Abdurakhman, Ibragimova M. Gulchehra, Achilova U. Ozoda**
IMMUNE THROMBOCYTOPENIA A MODERN VIEW OF DIAGNOSIS AND
TREATMENT: LITERATURE REVIEW.....26

PEDIATRIC SURGERY

5. **Kamolov J. Sardor, Mavlyanov Sh. Farxod, Yangiyev A. Baxtiyor**
BIOIMPEDANCE PARAMETERS IN PATIENTS WITH EMERGENCY ABDOMINAL
PATHOLOGY.....35
6. **Tuxtayev M. Firdavs, Mavlyanov Sh. Farxod, Mavlyanov X. Shavkat**
RESULTS OF BIOIMPEDANCE ANALYSIS IN CHILDREN WITH EMERGENCY
PATHOLOGY OF THE URINARY SYSTEM.....41
7. **Mavlyanov Sh. Farhod, Ulmasov G. Firdaus, Allazov N. Feruz, Mavlyanov Kh. Shavkat,
Tursunov E. Sanjar.**
SURGICAL TREATMENT OF A TUMOR OF THE ABDOMINAL CAVITY ISSUING
FROM THE WALL OF THE STOMACH IN A CHILD: A CLINICAL CASE.....46

RADIOLOGY

8. **Xalikulov Sh. Elbek, Sharopov Sh. Sadullo.**
NEUROSONOGRAPHY AS A METHOD OF INTRAOPERATIVE NAVIGATION IN THE
TREATMENT OF MULTILEVEL HYDROCEPHALIA.....52
9. **Usarov Sh. Mukhriddin**
OPTIMIZATION AND IMPORTANCE OF ULTRASOUND DIAGNOSTIC METHODS IN
THE CHOICE OF TACTICS FOR THE TREATMENT OF PATIENTS WITH CERVICAL
OSTEOCHONDROSIS.....56

OTORHINOLARYNGOLOGY

10. **Nasretdinova T. Makhzuna, Xayitov A. Alisher, Dustboboyev S. Dilshod**
MODERN ASPECTS IN THE DEVELOPMENT OF EXUDATIVE OTITIS MEDIA.....62
11. **Nasretdinova T. Makhzuna, Normirova N. Nargiza, Shadiev E. Anvar**
AUDITORY ADAPTATION IN PATIENTS WITH PERIPHERAL AND CENTRAL
HEARING IMPAIRMENT.....70

MORPHOLOGY

12. **Urinov M. Alisher, Otajonov O. Ilhom, Akhmedova B. Dilafruz**
STUDY OF CHANGES IN SOME BIOCHEMICAL INDICATORS OF BLOOD IN
SIMULATION OF EXPERIMENTAL LIVER DAMAGE.....76

13. **Nuraliev A. Nekqadam, Murotov F. Nurshod.**
THE RESULTS OF DETERMINING THE DEGREE OF INFLUENCE OF THE GENETICALLY MODIFIED SHADE ON THE REGULATORY MICROFLORA OF THE COLON OF LABORATORY ANIMALS.....81
14. **Khamidova M. Farida, Zhovlieva B. Mavlyuda**
MORPHOLOGICAL AND FUNCTIONAL FEATURES OF THE STRUCTURE OF THE BRONCHI IN EXPERIMENTAL CHRONIC OBSTRUCTIVE PULMONARY DISEASES.....91
15. **Sabirova Sh. Dilnoza, Oripov S. Firdavs**
MORPHOLOGICAL FEATURES OF THE ADRENAL CORT OF RAT OFFSPRING IN ONTOGENESIS UNDER THE CONDITIONS OF INTRAUTERINE EXPOSURE TO PESTICIDES THROUGH THE MOTHER'S ORGANISM (REVIEW ARTICLE).....100
16. **Boboev I. Askar, Oripov S. Firdavs**
MORPHOLOGY NEAR THE BALL-BLADYING PARENCHYMA OF THE RABBIT LIVER WITH EXPERIMENTAL CALCULOSIS CHOLECYSTITIS.....108
17. **Kurbonov R. Khurshed, Oripov S. Firdavs, Deev V. Roman**
EFFECT OF OCTACALCIUM PHOSPHATE AND ITS COMBINED FORMS ON BONE REGENERATION.....114

NEUROLOGY

18. **Kamalova I. Malika, Khaidarov K. Nodirjon, Teshayev Zh. Shukhrat.**
CLINICAL FEATURES OF SOME RISK FACTORS FOR STROKE IN WOMEN.....122
19. **Sheryigitova I. Nigina, Muzaffarova Sh. Nargiza, Khakimova Z. Sohiba.**
COGNITIVE AND ASTHENIC DISORDERS AFTER COVID-19.....129

ONCOLOGY

20. **Kuliev A. Aziz, Tursunov M. Odil, Ulmasov G. Firdavs, Urazov S. Numon, Toshov T. Alizhon**
FEATURES OF DEVELOPMENT OF MECHANICAL JAUNDICE IN GASTRIC CANCER AND METHODS OF ITS ELIMINATION.....136
21. **Polatova Sh. Jamilya, Tagaev A. Jasur**
GLOBAL STATUS OF THE PROBLEMS OF DIFFERENTIAL DIAGNOSIS OF MELANOMA AMONG PATIENTS WITH MELANOCYTIC LESIONS AND NEOPLASMS.....143
22. **Rakhimov M. Nodir, Abdurakhmonov A. Jurabek, Shakhanova Sh. Shakhnoza, Sulimova G.Olga**
PATOGENESIS OF PERITONEAL ASCITES IN RECURRENT OVARIAN CANCER.....152
23. **Djuraev D. Mirjalol, Shamuradov I. Ilxom**
THE ROLE OF ENDOSCOPIC STENTING IN ESOPHAGEAL CANCER COMPLICATED BY FISTULA.....159
24. **Alimkhodzhayeva T. Lola, Norbekova Kh. Munira, Zievidinova S. Soniya, Mirzayeva A. Matlyuba, Khusanova J. Makhinabonu**
CLINICAL SIGNIFICANCE OF TUMOR-INFILTRATING LYMPHOCYTES IN BREAST CANCER.....166
25. **Alimkhodzhayeva T. Lola, Norbekova Kh. Munira, Zievidinova S. Soniya, Mirzayeva A. Matlyuba, Khusanova J. Makhinabonu**
THE BASIC APPROACHES TO STUDYING THE LYMPHATIC SYSTEM IN BREAST CANCER(LITERATURE REVIEW).....177
26. **Rakhimov M. Nodir, Tulanov T. Begzod, Shakhanova Sh. Shakhnoza, Aslsnova M. Lobar**
PATHOGENETIC ASPECTS OF CANCER ANOREXIA.....192

OPHTHALMOLOGY

27. **Kadirova M. Aziza, Khasanova A. Dildora.**
CASE FROM PRACTICE: CONGENITAL ANOMALY OF OPTIC DISC EXCAVATION. «MORNING GLORY» SYNDROME.....202
28. **Allayarov T. Azimbek, Rizayev A. Jasur, Yusupov A. Amin, Xakimova Sh. Mavluda.**
THE STATE OF OPHTHALMOLOGICAL CARE AND ITS IMPROVEMENT IN PATIENTS WITH DIABETIC RETINOPATHY (LITERATURE REVIEW).....210

PEDIATRICS

29. **Tairova B. Sakina**
PREVALENCE OF ALLERGIC DISEASES AMONG CHILDREN WITH CONGENITAL HEART DEFECTS.....215
30. **Tairova B. Sakina, Mukhamadiyeva A. Lola**
IMMUNOLOGICAL ASPECTS IN YOUNG CHILDREN WITH CONGENITAL HEART DEFECTS.....220
31. **Tairova B. Sakina**
CONGENITAL HEART DEFECTS: AN IMMUNOLOGICAL PERSPECTIVE (LITERATURE REVIEW).....226
32. **Fayziyeva R. Ugilbibi, Normamato V. Kh. Dilmurod. Mamadiyeva N. Zarifa**
CHARACTERISTICS OF BRONCHOBSTRUCTIVE SYNDROME IN CHILDREN.....231

PSYCHIATRY

33. **Kenjaeva K. Nargiza, Rizaev A. Jasur, Umirov E. Safar, Baymirov L. Sanjar.**
CLINICAL DYNAMICS OF DEPENDENCE TO PSYCHOACTIVE SUBSTANCES AND ITS DETERMINANTS.....237
34. **Baymirov L. Sanjar, Ochilov U. Ulugbek, Turayev T. Bobir**
CLINICAL FEATURES OF THE ABUSE OF VARIOUS DRUGS IN PATIENTS WITH ALCOHOLISM.....247

REHABILITATION AND SPORTS MEDICINE

35. **Mavlyanova F. Zilola, Kim A. Olga, Xudoykulova V. Farida, Raxmatullina R. Luiza, Bulyakova A. Gulnaz, Akhmadeeva Leila.**
POSSIBILITIES OF PERSONALIZED REHABILITATION AFTER A STROKE USING TELETECHNOLOGIES AND PREDICTION OF OUTCOMES BASED ON CLINICAL AND NEURORADIOLOGICAL STUDIES.....252
36. **Kamilova T. Roza, Mavlyanova F. Zilola, Basharova M. Laylo, Isakova I. Lola, Burxanova L. Gulnoza.**
COMPARATIVE ASSESSMENT OF ACTUAL FOOD CONSUMPTION BY CHILDREN OF PRESCHOOL EDUCATIONAL ORGANIZATIONS WITH DIFFERENT DIETARY INTAKE.....261

STOMATOLOGY AND MAXILLOFACIAL SURGERY

37. **Latipova B. Sitora**
INVESTIGATION OF THE CLINICAL EFFICACY OF ORAL MUCOSA TREATMENT AFTER CHEMOTHERAPY: LITERATURE REVIEW.....270
38. **Abdullaev Sh. Dilmurod**
ANALYSIS OF THE RESULTS OBTAINED AND SOME FEATURES OF CYTOKINE PROFILE IN MIXED SALIVA OF PATIENTS WITH GASTROINTESTINAL TRACT DISEASE.....279

39. **Rizaev A. Jasur, Akhmedov A. Alisher**
IMPROVING DENTAL CARE IN UZBEKISTAN USING A CONCEPTUAL APPROACH TO IMPROVE ITS QUALITY.....287
40. **Sharopov G. Sanzhar, Tojiev I. Feruz, Azimov I. Mukhammadjon, Inoyatov Sh. Amrillo, Ismoilkhodjaeva G. Komila**
CLINICAL AND RADIOLOGICAL MANIFESTATIONS OF SECONDARY MAXILLARY DEFORMITIES IN PATIENTS WITH UNI- AND BILATERAL CLEFT LIP AND PALATE AFTER PRIMARY LIP AND PALATE SURGERIES.....294

THERAPY

41. **Ermatov J. Nizom, Nasirdinov Z. Mavlonjon, Ishmetov P. Sherzod, Oltiev Sh. Amrillo, Kasimova E. Kizilgul.**
EVALUATION OF THE EFFECTIVENESS OF THE DAILY DIET OF SCHOOLCHILDREN SUFFERING FROM IRON DEFICIENCY ANEMIA FROM ENRICHED LOCAL PROTEIN-CONTAINING PRODUCTS.....301
42. **Ermatov J. Nizom, Abdulkhakov U. Ikhtiyor, Shukurov N. Anvar, Nasirdinov Z. Mavlon, Kasimova E. Kizilgul**
HYGIENIC FEATURES OF DIABETES PREVENTION.....308
43. **Tashkenbayeva N. Eleonora, Esankulov O. Mukhammad**
SIGNIFICANCE OF UROMODULIN IN THE DEVELOPMENT AND PROGRESSION OF CHRONIC KIDNEY DISEASE.....318
44. **Tairov R. Doston, Berdiev H. Doniyor**
STRUCTURAL CHANGES IN THE CARDIOVASCULAR SYSTEM IN PATIENTS WITH GOUT.....331
45. **Rizaev A. Jasur, Qilichev A. Anvar, Olimjonova J. Farangiz**
RISK FACTORS FOR CARDIOVASCULAR DISEASE AFTER CORONARY ARTERY BYPASS GRAFTING IN PATIENTS WITH ISCHEMIC HEART DISEASE.....339
46. **Isirgapova N. Sarvinoz, Sultonov N. Nodir**
IMPACT OF HORMONAL CHANGES ON THE QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE 5TH STAGE.....349
47. **Yakubov V. Abduljalol, Pulaniva I. Nargiza, Saidova A. Shakhnoza, Musayeva J. Lola**
PROSPECTIVE DIRECTIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE.....360
48. **Xaydarova D. Dilrabo, Tashkenbaeva N. Eleonora**
CLINICAL CHARACTERISTICS OF THE COURSE AND CRITERIA FOR DIAGNOSTICS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN PATIENTS WITH COVID-19 PNEUMONIA.....366

PHARMACOLOGY

49. **Boboyev M. Behzod**
CLINICAL EVALUATION OF THE CHRONIC TOXICITY OF THE NEW DRUG «TIOSIN», CONSISTING WITH A COMPLEX COMBINATION OF THE MICROELEMENT ZINC AND LIPOIC ACID.....376
50. **Allazov A. Salakh. Iskandarov N. Yusuf**
LOCAL HEMOSTATIC IN UROLOGICAL BLEEDING.....383

SURGERY

51. **Shodmonov A. Akbar, Kurbaniyazov B. Zafar, Askarov A. Pulat**
EVALUATION OF THE RESULTS OF THE TREATMENT OF NON-SPECIFIC ULCERATIVE COLITIS WITH THE APPLICATION OF PLASMAPHERESIS.....390
52. **Rizayev A. Jasur, Kurbaniyazov B. Zafar, Saidov B. Zohir, Abduraxmanov Sh. Diyor.**
ANTEGRADE ANGIOSCLEROTHERAPY OF THE LEFT TESTICULAR VEIN.....397

53.	Nazarov N. Zokir SURGICAL TREATMENT OF COMPLICATED FORMS OF CHOLELITHIASIS IN ELDERLY AND SENILE PATIENTS (LITERATURE REVIEW).....	407
54.	Shamratov Z. Shokir, Akhmedov M. Yusuf, Yusupov S. Anvar, Saidov A. Maksud MYOCARDIAL PROTECTION METHODS IN CARDIAC SURGERY PRACTICE (REVIEW ARTICLE).....	417
55.	Ruziboev A. Sanjar, Yunusova F. Guzal, Yunusov T. Oybek EFFICIENCY OF APPLICATION OF DOMESTIC HEMOSTATIC IMPLANT "HEMOBEN" IN SEVERELY BURNED PATIENTS.....	424
56.	Abdullaev A. Sayfulla, Xujabaev T. Safarboy, Dusiyarov M. Muhammad TACTICS OF TREATMENT OF ACUTE COMMERCIAL INTESTINAL OBSTRUCTION.....	431
57.	Sherbekov A. Ulugbek, Xaydarova O. Laylo, Abdurakhmanov Sh. Diyor CLINICAL FEATURES OF HERNIOPLASTY AND ABDOMINOPLASTY WITH COMPLICATED ABDOMINOPTOSIS IN VENTAL HERNIAS.....	440
58.	Sherbekov A. Ulugbek, Xaydarova O. Laylo SURGICAL TREATMENT OF VENTAL HERNIAS IN PATIENTS WITH MORBID OBESITY AND ABDOMINOPTOSIS.....	446
59.	Umedov A. Xushvaqt OUR EXPERIENCE IN CONSERVATIVE TREATMENT OF SPLEEN INJURY IN CLOSED ABDOMINAL TRAUMA.....	451
60.	Umedov A. Xushvaqt POSSIBILITIES OF VIDEOLAPAROSCOPIC DIAGNOSIS AND TREATMENT OF ISOLATED AND COMBINED LIVER DAMAGE.....	456
61.	Sattarov S. Inayat, Matmurotov J. Kuvondik, Yakubov Y. Ilyosbek, Rakhimov D. Dadakhon. WAYS TO IMPROVE REVASCULARIZATION RESULTS IN PATIENTS WITH DIABETIC FOOT SYNDROME.....	461

ORIGINAL ARTICLES

62.	Giyasov A. Zaynitdin, Khaydarov R. Khasanali, Siddikov U. Bokijon ANALYSIS OF COMMISSION FORENSIC MEDICAL EXAMINATIONS RELATED TO THE ACTIVITIES OF OBSTETRICIAN-GYNECOLOGISTS.....	468
63.	DAMINOV Feruz Asatullaevich ASPECTS OF SURGICAL TREATMENT OF DEEP BURN IN ELDERLY AND SENILE AGE.....	475
64.	SAMIEV Asliddin Sayitovich, KHAMIDULLAEVA Mohinur Maksatullo qizi COMPLEX REHABILITATION MEASURES IN PATIENTS SUFFERING WITH RADICULOPATHIES OF THE VERTEBROGENOUS LUMBAR AREA.....	481



УДК: 616.298.67/539-1.24

Abdullaev Dilmurod SharifovichCandidate of Medical Sciences, Associate Professor
Tashkent State Institute of Stomatology**ANALYSIS OF THE RESULTS OBTAINED AND SOME FEATURES OF CYTOKINE PROFILE IN MIXED SALIVA OF PATIENTS WITH GASTROINTESTINAL TRACT DISEASE**

For citation: Abdullaev Sh. Dilmurod. Analysis of the results obtained and some features of cytokine profile in mixed saliva of patients with gastrointestinal tract disease// Journal of Biomedicine and Practice. 2023, vol. 8, issue 4, pp. 279-286

<http://dx.doi.org/10.5281/zenodo.8316904>**ANNOTATION**

Objective: To study the obtained data and some features of cytokine profile in mixed saliva of patients with gastrointestinal tract disease

Methods: 140 patients with gastrointestinal tract pathology were examined, including 98 men (70%) and 42 women (30%), mean age - 51.9 years. According to endoscopic examination, the patients had lesions of different parts of the GI tract (chronic gastritis; peptic ulcer disease of the stomach and 12-peritoneum). The control group included 25 practically healthy individuals. Diagnosis of the lesion of different GIT departments was based on classical criteria and was carried out taking into account clinical-endoscopic, functional and morphological data. Verification of chronic gastritis was carried out according to classification signs.

Obtained results: it was found that the spectrum of oral cavity lesions in various concomitant diseases is wide. At the same time, they develop pathological conditions in oral cavity tissues, and on their background there is a reception of various preparations for their own correction.

Conclusions. Thus, the level of interleukin-4 in the mixed saliva of patients with GI disease decreased by 23% relative to the comparison group data. At the same time, the level of IL-6 in the mixed saliva of the examined patients exceeded the initial level in 2.4 times. IL-6 is known to be an inducer of inflammatory reaction and triggers the synthesis of acute phase proteins in the liver (C-reactive protein, serum amyloid A, etc.), as well as reduces the production of fibronectin, albumin and transferrin in the liver. The key anti-inflammatory factor IL-10. is known to inhibit the production of TNF α , IL-1 β and IL-6 and inhibit the expression of major histocompatibility complex class II.

Keywords: cytokine profile, gastrointestinal tract, oral cavity

Абдуллаев Дилмурод Шарифович

кандидат медицинских наук, доцент

Ташкентский государственный институт стоматологии

АНАЛИЗ ПОЛУЧЕННЫХ РЕЗУЛЬТАТОВ И НЕКОТОРЫЕ ОСОБЕННОСТИ ЦИТОКИНОВОГО ПРОФИЛЯ В СМЕШАННОЙ СЛЮНЕ У ПАЦИЕНТОВ С ЗАБОЛЕВАНИЕМ ЖЕЛУДОЧНО-КИШЕЧНОГО ТРАКТА

АННОТАЦИЯ

Цель: изучить полученные данные и некоторые особенности цитокинового профиля в смешанной слюне у пациентов с заболеванием желудочно-кишечного тракта

Методы: Обследовано 140 пациента с патологией желудочно-кишечного тракта, из них 98 мужчин (70%) и 42 женщин (30%), средний возраст - 51,9 лет. Согласно эндоскопическому исследованию у пациентов выявлялись поражения различных отделов ЖКТ (хронический гастрит; ЯБЖДК - язвенная болезнь желудка и 12-перстной кишки). В контрольную группу вошли 25 практически здоровых лиц. Диагностика поражения различных отделов ЖКТ базировалась на классических критериях и осуществлялась с учетом клинико-эндоскопических, функциональных и морфологических данных. Верификация хронического гастрита проводилась по классификационным признакам.

Полученные результаты: обнаружено что, спектр поражений полости рта при различных сопутствующих заболеваниях широк. При этом, они развивают патологических состояний в тканях ротовой полости, и на их фоне имеет место прием различных препаратов для собственной коррекции.

Выводы. Таким образом, снижение уровня интерлейкина-4 в смешанной слюне больных заболеванием ЖКТ на 23% относительно данных группы сравнения. При этом, уровень ИЛ-6 в смешанной слюне у обследованных пациентов превысил исходный уровень в 2,4 раза. Как известно ИЛ-6 является индуктором воспалительной реакции и запускает синтез белков острой фазы в печени (С-реактивного белка, сывороточного амилоида А и др.), а также снижает продукцию фибронектина, альбумина и трансферрина в печени. Как известно, ключевой противовоспалительный фактор ИЛ-10. ингибирует продукцию TNF α , IL-1 β и IL -6 и препятствует экспрессии главного комплекса гистосовместимости II класса.

Ключевые слова: цитокиновый профиль, желудочно-кишечный тракт, ротовая полость

Abdullayev Dilmurod Sharifovich
tibbiyot fanlari nomzodi, dotsent
Toshkent davlat stomatologiya instituti

OSHQOZON-ICHAK TRAKTI KASALLIGI BO'LGAN BEMORLARDA OLINGAN NATIJALARNI TAHLIL QILISH VA ARALASH TUPURIKDAGI SITOKIN PROFILINING BA'ZI XUSUSIYATLARI

ANNOTATSIYA

Maqsad: oshqozon-ichak trakti kasalligi bo'lgan bemorlarda aralash tupurikdagi sitokin profilining topilmalari va ba'zi xususiyatlarini o'rganish.

Material va metodlar: Oshqozon-ichak trakti patologiyasi bo'lgan 140 bemor tekshirildi, ulardan 98 nafari erkaklar (70%) va 42 nafari ayollar (30%), o'rtacha yoshi 51,9 yosh. Endoskopik tekshiruvga ko'ra, bemorlarda oshqozon - ichak traktining turli qismlarining shikastlanishi aniqlandi (surunkali gastrit, oshqozon va o'n ikki barmoqli ichakning oshqozon yarasi). Nazorat guruhiga 25 nafar sog'lom shaxs kirdi. Oshqozon-ichak traktining turli bo'limlariga zarar etkazish diagnostikasi klassik mezonlarga asoslangan va klinik-endoskopik, funktsional va morfologik ma'lumotlarni hisobga olgan holda amalga oshirilgan surunkali gastritni tekshirish tasniflash xususiyatlariga muvofiq amalga oshirildi.

Natijalar: turli xil qo'shma kasalliklarda og'iz bo'shlig'ining shikastlanish spektri keng ekanligi aniqlandi. Shu bilan birga, ular og'iz bo'shlig'i to'qimalarida patologik sharoitlarni rivojlantiradilar va ularning fonida o'zlarining tuzatishlari uchun turli xil dorilar qabul qilinadi.

Xulosa. Shunday qilib, oshqozon-ichak trakti kasalligi bilan og'rigan bemorlarning aralash tupurigidagi interleykin-4 darajasining taqqoslash guruhi ma'lumotlariga nisbatan 23% ga kamayishi.

Shu bilan birga, tekshirilgan bemorlarda aralash tupurikdagi il-6 darajasi boshlang'ich darajadan 2,4 baravar oshdi. Ma'lumki, il - 6 yallig'lanish reaksiyasining induktori bo'lib, jigarda o'tkir fazali oqsillarning sintezini boshlaydi (C-reaktiv oqsil, sarum amiloid a va boshqalar), shuningdek jigarda fibronektin, albumin va transferrin ishlab chiqarishni kamaytiradi. Ma'lumki, il-10 ning asosiy yallig'lanishga qarshi omili. Tnfa, IL-1b va IL -6 ishlab chiqarishni inhiye qiladi va II darajali asosiy gistokompatibillik kompleksining ifodalanishiga to'sqinlik qiladi.

Kalit so'zlar: sitokin profili, oshqozon-ichak trakti, og'iz bo'shlig'i

Introduction: Immunological mechanisms play a leading role in the pathogenesis of inflammatory-destructive processes in the periodontium. That is why clinical manifestations of chronic generalised periodontitis depend not so much on the pathogenicity and virulence of the corresponding microflora as on the nature of bacterial-gostal relationships, i.e. largely on the degree of reactivity of the macroorganism, determined by the functional state of the immune system. Therefore, an important stage in understanding the nature of inflammatory periodontal diseases is the study of those immunological factors (cytokines and antibodies), as well as enzymes that can cause shifts in the morpho-functional state of the supporting apparatus of the tooth, as well as cause the corresponding clinic of this pathology. Cytokines are protein-peptide factors produced by cells and carrying out short-range regulation of intercellular and intersystem interactions. Not only immunocompetent but also endothelial cells can be cytokine producers. It has been established that the same cytokine can be produced by cell types of different histogenetic origin in different organs [1]. The functions of cytokines include regulation of immune response, inflammatory reactions, haemopoiesis, participation in apoptosis, angiogenesis, chemotaxis [3]. To date, the cytokine system consists of more than 300 polypeptide substances. The most well studied are cytokines of the immune system, which are secreted during the realisation of mechanisms of general and local immunity, showing their activity at extremely low concentrations. These molecules can be considered as mediators of inflammatory reactions, possessing, at the same time, endocrine, paracrine and autocrine types of regulation [5]. In the work of cytokines, the phenomena of antagonism and synergism, their interchangeability, as well as pleiotropy, i.e. the ability of the same mediator to influence different processes, act on many types of cells, causing different effects, are noted [4]. Interleukins are of the greatest clinical and immunological interest. According to the mechanism of action, these polypeptides can be divided into proinflammatory (inducing inflammatory response); anti-inflammatory (limiting the development of inflammatory response); and regulators with their own effector functions (cytotoxic, antiviral, etc.) [2]. Since cytokines are mediators of local action, the most indicative and reliable is the assessment of their concentration in the corresponding tissues and natural fluids (e.g., gingival fluid). The diagnostic value of cytokines lies in the fact that the study of their level makes it possible to judge the functional activity of different types of immunocompetent cells, the severity and severity of the inflammatory process, the probability of its chronicity, transition to the systemic level, as well as the prognosis [4]. Cytokine synthesis increases dramatically as a result of "tissue stress", i.e. it is an inducible process and is practically absent outside the inflammatory reaction and immune response [2]. For example, when exposed to an infectious agent, in particular - molecules of lipopolysaccharides, peptidoglycans and muramyl dipeptides, which are part of the cell wall of Gram-negative periodontopathogenic bacteria, there is an activation of macrophages, increasing the production of proinflammatory cytokines (IL-1 β , TNF- α , etc.). These cytokines circulating in the blood stimulate the secretion of acute phase proteins [6]. In case of late elimination of a proinflammatory agent (antigen) and transition of the process into a chronic form (with increased activity of negative regulators inhibiting inflammation, e.g. IL-10) - there will be significant destructive processes. Thus, monocytes and macrophages activated by pathogens synthesise a whole cascade of cytokines, causing an imbalance between the pro- and anti-inflammatory pool, which, as mentioned above, leads to resorptive phenomena. The study of these processes formed the basis of the cytokine concept of the development of chronic inflammation, including in the periodontal complex [8]. The most pronounced, damaging effect on periodontal tissues is characteristic of proinflammatory IL-1 β and TNF- α . In particular, there is a direct

correlation between the severity of periodontitis and the level of TNF- α in venous blood [2]. In turn, IL-1 β is one of the main mediators of pathological process generalisation in the periodontium [9]. IL-1 β producers are macrophages, to a lesser extent dendritic cells, endothelium, and fibroblasts. IL-1 β stimulates the emigration of PMNL from bone marrow, causes exocytosis of lysosomal enzymes and free radicals by phagocytes, stimulates mast cell degranulation, activates prostacyclin production, and the formation of acute phase proteins by hepatocytes, which is the reason for its pyrogenic effect[8]. IL-1 β and TNF- α stimulate bone tissue resorption (activate osteoclasts); adversely affect tissue repair by inhibiting the process of resynthesis of collagen fibres by fibroblasts; stimulate collagenase synthesis. Moreover, the above activity is manifested at insignificant concentrations of these polypeptides [11]. It has been established that during the progression of generalised periodontitis there is a significant increase in the level of these cytokines both in gingival tissues and gingival fluid [14]. Moreover, the formed cytokines not only adversely affect the surrounding tissues, but also stimulate further activation of the cells synthesising them, which shows their paracrine regulation[13]. With chronicity of inflammatory processes in the periodontium (which is especially characteristic of the elderly), there is an imbalance between cytokines, which leads to hyperactivation of osteoclasts. Accordingly, the degree of degenerative and destructive lesions of alveolar bone in generalised periodontitis is directly related to the level of accumulated cytokines [12]. IL-8 belongs to the chemokine family and is a low molecular weight proinflammatory cytokine. Its production is carried out under the influence of bacterial endotoxins, as well as some cytokines (TNF and IL-1). IL-8 has the ability to activate neutrophils and monocytes, initiating their chemotaxis to the focus of inflammation, and can have a destructive effect on bone tissue. Increased level of this cytokine correlates with acute and chronic inflammatory conditions, tissue neutrophil infiltration. When studying the cytokine profile of periodontitis patients, an increase in IL-8 in venous blood and gingival fluid was also found [7]. In addition, increased secretion of anti-inflammatory IL-10 plays a special role in the pathogenesis of periodontitis and bone resorption, which does not allow the development of a full-fledged inflammatory response, the main task of which is the elimination of the pathogen. As a result, a sluggish course of periodontitis is clinically observed against the background of pronounced destructive processes in the periodontal complex [12]. Factors of humoral immunity, primarily antibodies - immunoglobulins produced by plasma cells (activated B-lymphocytes), which are specific for a particular antigen, play an important role in the pathogenesis of chronic generalised periodontitis. Immunoglobulins of three classes are most associated with periodontal tissues: IgA, IgG and IgM [15]. It has been established that immunoglobulins enter the gingival fluid from the bloodstream. Thus, the factors of local immunity determined in the gingival fluid are a reflection of the general humoral immunity and correlate with it. In its turn, the gingival sulcus can be positioned as a kind of "representative" of the general immunity in the periodontal complex [16]. At the same time, a certain share of immunoglobulins is formed locally, in the tissues of marginal periodontium, so the origin of these antibodies determined during inflammation has both systemic and local character[10]. It is established that with the progression of periodontal pathology there is a gradual decrease in the level of nonspecific defence and an increase in the activity of specific factors. In particular, in inflammatory destructive processes in the periodontal complex there is an increase in the level of immunoglobulins, which is the result of pronounced antigenic stimulation as bacterial invasion spreads under the gingiva. There is an active synthesis of antibodies, with their subsequent transudation into the gingival fluid[9]. Elevated IgA levels indicate the presence of acute or chronic infection (including bacterial origin). Immunoglobulins of class M carry out antibacterial immunity and are produced first in response to an infectious factor. Immunoglobulins of class G are the leading effectors of humoral immunity. It has been established that the bulk of antibodies to bacteria belong to IgG [11]. High levels of sIgA, IgG, and complement fractions are found in the contents of periodontal pockets. In case of direct reaction of 23 antibodies with antigens - cytotoxic reactions are observed, which leads to the destruction of tissue structures. It is established that the most frequent cytotoxic antibodies are represented by immunoglobulins of G and M classes [13]. High activity of enzymes, primarily lactate dehydrogenase (LDH) and alkaline phosphatase (ALP), plays an important role in the development and progression of inflammatory and destructive processes

in the periodontal complex [12]. The sources of enzymes in the periodontal complex are host cells (macrophages, PMNL, fibroblasts and osteoclasts), as well as microorganisms of dental plaque. The appearance of active forms of enzymes in gingival fluid initiates tissue destruction processes [10]. Lactate dehydrogenase (LDH) is an intracellular, cytoplasmic, glycolytic enzyme that catalyses the reversible hydrogen splitting from the lactic acid molecule. The extracellular localisation of this enzyme indicates cell death and, consequently, tissue damage, which is observed when gingival epitheliocytes are destroyed and the enzyme is released into the interstitium, which leads to an increase in the level of this enzyme in gingival and oral fluids [6]. When LDH concentration increases, there is a disruption of the functional activity of a number of immunocompetent cells, in particular neutrophils, as well as a decrease in synthetic activity in tissues [5]. In the presence of periodontal pockets, as well as the progression of destructive processes in the periodontium, there is a significant increase in LDH activity, and its increase correlates with the severity of periodontitis [3]. One of the most reliable indicators of bone metabolism is the determination of alkaline phosphatase, which catalyses the detachment of phosphoric acid from its organic compounds. The enzyme is located on the surface of the cell membrane and takes part in phosphorus transport [14]. Numerous histochemical studies confirm the active participation of alkaline phosphatase in bone tissue metabolism. In particular, a significant increase in the content as well as activity of alkaline phosphatase is determined during bone tissue destruction [8]. In addition to osteoblasts, this enzyme is found in lysosomes of neutrophils, as well as in gingival epithelial cells. Moreover, the increase of alkaline phosphatase activity in gingival fluid can be an indicator of destructive processes observed in periodontitis. A direct correlation between the activity of alkaline phosphatase, the level of bone tissue resorption, and the nature of the course of inflammatory processes in the periodontium has been established [7]. Thus, the analysis of cytokine profile, determination of antibody levels and enzyme activity in gingival fluid and venous blood of individuals suffering from chronic generalised periodontitis is a necessary stage of diagnosis, allowing to assess the degree and severity of inflammatory-destructive processes in the periodontium, as well as to choose the most optimal, etiopathogenetically justified treatment.

Aim of the study: Study of immunological features of mixed saliva in patients with gastrointestinal tract disease.

Material and methods of research: We have investigated 140 patients with pathology of gastrointestinal tract, including 98 men (70%) and 42 women (30%), average age - 51.9 years in outpatient conditions of Tashkent State Dental Institute for the period 2020-2023. According to endoscopic examination, the patients had lesions of different parts of the GI tract (chronic gastritis; peptic ulcer disease of the stomach and 12-peritoneum). The control group included 25 practically healthy individuals. Diagnosis of the lesions of various GI tract sections was based on classical criteria and was carried out taking into account clinical-endoscopic, functional and morphological data. Verification of chronic gastritis was carried out according to classification signs proposed by the International Association of Gastroenterologists on the basis of endoscopic and morphological criteria. Patients and healthy controls were monitored according to a unified programme including general clinical examination, esophagogastroduodenoscopy (EGDS). Biomaterial was collected in the morning hours, on an empty stomach into graduated tubes. In all patients, collection of mixed saliva samples was performed initially before drug administration. Before starting the procedure, the patient rinsed the mouth with distilled water for 30 seconds, followed by 5 minutes of rest. The patient then swallowed all accumulated saliva, after which direct collection of material began for 15 minutes. When finished, the tube was tightly capped, placed in an ice container and transported to the laboratory within an hour and a half. In the laboratory, the tubes were centrifuged at 3000 rpm for 10 minutes at 4°C, after which the saliva sample was frozen and stored at -80°C until examination. Pro- and anti-inflammatory cytokines (IL-1, IL-2, IL-4, IL-6, IL-8, IL-10 and TNF-a), as well as alpha-defensin 1-3, were determined in blood and oral fluid by solid-phase enzyme-linked immunosorbent assay using test systems produced by Vector-Best CJSC (Novosibirsk, Russia). Statistical processing of the data was performed on a personal computer using a standard software package for applied

statistical analysis (Statistica for Windows v. 7.0). The value of $p < 0.05$ was used to assess the reliability of differences.

RESULTS: It is known that the spectrum of oral cavity lesions in various concomitant diseases is wide. At the same time, concomitant diseases contribute to the development of pathological conditions in the tissues of the oral cavity, and on their background there is the use of various drugs for their correction. Gerontological population, which is the main consumer of medicines, should not be ignored. When analysing the nosologies of gastrointestinal tract diseases, atrophic and chronic gastritis prevailed. According to the data obtained, 63% of patients with gastrointestinal pathology noted the presence of bad breath (halitosis). Dryness of the oral cavity was reported by 28% of the respondents. Colour change of tongue and gingiva was noted by 52% of respondents. Burning sensation in the oral cavity was noted by 8% of respondents, and 12% of patients indicated the presence of hypersalivation. To determine the intensity of the carious process in patients with GI pathology, the CPP index was used. The KPU index in patients was 8.48 ± 0.91 , which corresponds to the average level of caries intensity. The number of filled teeth ranged from 1 to 6. The number of extracted teeth was insignificantly lower than the number of filled teeth, it ranged from 1 to 24 teeth. The values of the KPU index were significantly positively dependent on the diagnosis of GI nosology. The lowest values of the CPU index were present in patients with chronic gastritis, and the highest in patients with CJD. In addition to clinical examination of oral tissues, in patients with GI pathology, a study of mixed saliva, which reflects the changes occurring in the oral cavity, was performed. It is known that cytokines, possessing the ability to regulate the processes of proliferation, differentiation, functional activity of cells, apoptosis, haemopoiesis, angiogenesis, as well as the ability to carry out intercellular and intersystem interactions, determine the type, strength and duration of the immune response, can have both pro- and anti-oncogenic effects. Their mechanism of action is realised in an extra- and/or intracellular way through binding to specific receptors located on the cytoplasmic membrane of cells or circulating in soluble form. IL-1 α and IL-1 β are produced by activated macrophages, keratinocytes as inactive precursor protein molecules and are converted into active cytokines by the action of either caspase-1 protease or IL-1-converting enzyme (ICE). The ability of IL-1 β to inhibit gastric acid formation is realised both directly, through its effect on receptors of parietal cells, and indirectly, through stimulation of synthesis of PG E₂, which is a strong inhibitor of hydrochloric acid secretion, and through activation of receptors in the central nervous system, located in the anterior hypothalamic region in the paraventricular nucleus.

Our studies have shown an average 3.6-fold increase in IL-1 α concentrations in mixed saliva in patients with gastrointestinal tract disease compared to healthy patients. High values of IL-1 α in blood in patients with gastrointestinal tract disease most likely indicate the development of chronic inflammatory process. This condition is characterised by increased production of cytokines with proinflammatory effects, i.e. cytokines in these pathological processes play the role of both aggression and protection factors. Their content depends on the etiological factor, variant of course, stage, duration of chronic inflammatory and destructive disease. In response to chronic inflammation of the gastrointestinal mucosa, there is an induction of interleukin-8 secretion by macrophages. As is known, activating neutrophils, IL-8 leads to their degranulation, release of lysosomal enzymes, leukotrienes, which have a damaging effect on the gastrointestinal mucosa. In addition, increased IL-8 levels are also found in peripheral blood regardless of localisation. In our studies, we observed an increase in the level of IL-8 in mixed saliva in patients with gastrointestinal tract disease on average 3 times relative to the indicators of healthy individuals. The pro-inflammatory cytokine tumour necrotising factor α (TNF- α) plays an important role in the formation of the inflammatory response. TNF- α is considered the strongest stimulus for IL-1 β production and is synthesised by T-lymphocytes and macrophages. This cytokine is multifunctional and plays a predominant role in the formation of local and general pathological processes, in particular, it activates the synthesis of pro-inflammatory interleukins, stimulates T- and B-lymphocytes, regulates the intensity of inflammation, increases the phagocytic activity of monocytes, nitric oxide formation, which also takes part in the implementation of physiological processes and inflammatory response in the mucosa of the gastroduodenal region. As can be seen from the presented results of studies, the level of tumour necrotising factor α was

increased relative to the indicators of the comparison group by 1.6 times. Prolonged and pronounced increase of TNF- α in mixed saliva in patients with GIT disease may contribute to the imbalance between the osteoforming function of osteoblasts and osteo-destructive function of osteoclasts towards hyperactivation of the latter in the dentoalveolar system.

Conclusions: Thus, the increase in IL-4 level in this situation probably has a compensatory character in relation to pro-inflammatory cytokines and acts as a factor stabilising the course of the disease. In addition, it is indicated that the level of TNF- α and IL-6 can indirectly judge the activity of the inflammatory process in the gastroduodenal zone. The analysis of the obtained results of the study, presented in Table 1, indicates a decrease in the level of interleukin-4 in the mixed saliva of patients with GIT disease by 23% relative to the data of the comparison group. At the same time, the level of IL-6 in the mixed saliva of the examined patients exceeded the initial level by 2.4 times. IL-6 is known to be an inducer of inflammatory reaction and triggers the synthesis of acute phase proteins in the liver (C-reactive protein, serum amyloid A, etc.), as well as reduces the production of fibronectin, albumin and transferrin in the liver. The key anti-inflammatory factor IL-10. is known to inhibit the production of TNF α , IL-1 β and IL -6 and inhibit the expression of major histocompatibility complex class II. One of the markers of activation of the inflammatory process is considered to be the level of antibacterial proteins defensins. We studied the content of a-defensins (HNP1-3) in the saliva of patients with GI diseases. As can be seen from the presented research results, the content of a-defensins 1-3 in the oral fluid of the patients of the main group and healthy individuals presented in Table 1 indicates a reduced secretion of a-defensins 1-3 in the oral fluid of the main group relative to the indicators of the comparison group. The identified evidence suggests inactivation of a-defensins, which may lead to increased microbial colonisation and increase the risk of viral and bacterial infections in the oral cavity. Low levels of diphensins in the mixed saliva of patients with GI disease contribute to decreased IL-8 secretion and progression of the inflammation process in the oral mucosa. Thus, when studying the content of cytokines and antimicrobial peptide in mixed saliva of patients with GI disease, the predominance of pro-inflammatory cytokines over anti-inflammatory cytokines and a decrease in the level of antimicrobial peptide were noted, which may activate bone resorption. In general, the identified changes may lead to an imbalance in the local immune response of mucous membranes and the development of both autoimmune and inflammatory diseases of the oral cavity.

REFERENCES / СНОСКИ / ИҚТИБОСЛАР

1. Akbiyeva D.S. The role of cytokines in the development of diseases of the gastroduodenal zone // Modern problems of science and education. - 2017. - № 2. С 64-69 Sims J.E., Nicklin M.J., Bazan J.F., Barton J.L., Busfield S.J., Ford J.E., Kastelein R.A., Kumar S., Lin H., Mulero J.J., Pan J., Pan Y., Smith D.E., Young P.R. A new nomenclature for IL-1-family genes. Trends Immunol. 2001; 22: 536–537.
2. Novye chleny tsitokinov interleikina-1 i ikh rol' v destruktivnykhvospalitel'nykh zabolevaniyakh. Med. al'manakh. 2011;5 (18): 274–276.
3. Ferrari D., Pizzirani C., Adinolfi E., Lemoli R.M., Curti A., Idzko M., Panther E., Di Virgilio F. The P2X7 receptor: a key player in ИЛ-1 processing and release. J. Immunol. 2006;176: 3877–3883.
4. Казеко Л.А. Возможности диагностики заболеваний периодонта с использованием противомикробных пептидов слюны и десневой жидкости // Современная стоматология. - 2016. - №.1. - С.11-16.
5. Пантелеев П. В., Болосов И. А., Баландин С. В., Овчинникова Т. В. Строение биологические функции Р-шпилечных антимикробных пептидов. Журнал «АКТА НАТУРЭ»-2015. - Т. 7. - № 1 (24). - С.37-47.
6. Ali Adem Bahar, Dacheng Ren. Antimicrobial Peptides//Pharmaceuticals (MDPI). - 2013. - Vol.6 (12). - P.1543-1575.

7. Alexandre L. Pereira, Gilson C. Franco, Sheila C. Cortelli.. Influence of Periodontal Status and Periodontopathogens on Levels of Oral Human P-defensin-2 in Saliva // *Journal of Periodontology*.-2013. - V.84. - №1. - P.1445-1453.
8. Henrik Dommisch S0ren Jepsen. Diverse Functions of Defensins and Other Antimicrobial Peptides in Periodontal Tissues // *Journal of Periodontology*. -2015.- V.69. - №1. -P.96-110.
9. Вавилова Т.П., Янушевич О.О., Островская О.Г. Слюна. Аналитические возможности и перспективы. М.: БИНОМ; 2014.
10. Будихина А.С., Пинегин Б.В. Дефензины — многофункциональные катионные пептиды человека. Иммунопатология, аллергология, инфектология. 2008;2:31-40.
11. Ericksen B, Wu Z, Lu W, Lehrer RI. Antibacterial activity and specificity of the six human alfa-defensins. *Antimicrobial Agents and Chemotherapy*. 2005;49(1):269-275.doi: 10.1128/AAC.49.1.269-275.2005.
12. Rizaev J.A, Rahimov N.M., Kadirov X.X., Shaxanova Sh.Sh. (2023). Oncoepidemiological assessment of the incidence and mortality of prostate cancer for the period 2015-2020 in the cross section of the republic of uzbekistan and individual regions. *Open Access Repository*, 4(3), 1108–1113. <https://doi.org/10.17605/OSF.IO/J3KWB>
13. Abiko Y, Saitoh M, Nishimura M, Yamazaki M, Sawamura D, Kaku T. Role of α -defensins in oral epithelial health and disease. *Medical Molecular Morphology*. 2007;40(4):79-184.doi: 10.1007/s00795-007-0381-8.
14. Lehrer R.I., Lu W. α -Defensins in human innate immunity // *Immunol. Rev.* — 2012. — Vol. 245, N 1. — P. 84-112.
15. Maksudov Dilshod D., Musurmanov Fazliddin I. et al. "Development of a Comprehensive Programme for the Comprehensive Treatment of Patients with Maxillofacial Phlegmon with Viral Hepatitis B." *JournalNX*, vol. 7, no. 02, 2021, pp. 191-198.
16. Maksudov, D., Musurmanov, F., & Nodirhonov, S. (2021). Effectiveness of the complex treatment of odontogenic phlegmon of the maxillofacial region in patients. *Збірник наукових праць SCIENTIA*. вилучено із <https://ojs.ukrlogos.in.ua/index.php/scientia/article/view/10529>
17. Маннанов, Ж., Мусурманов, Ф., & Абдуллажонова, Ш. (2022). Защитные средства-важный фактор при оказании неотложной помощи у больных с флегмонами челюстно-лицевой области при covid-19. *Дни молодых учёных*, 1(1), 64–66. извлечено от <https://inlibrary.uz/index.php/young-scientists/article/view/15058>
18. Гришин Д.В., Соколов Н.Н. Дефензины — естественные пептидные антибиотики высших эукариот // *Биомедицинская химия*. 2014. Т. 60. № 4. С. 438—447.
19. Gursoy U.K., Kononen E., Luukkonen N., Uitto V.J. Human neutrophil defensins and their effect on epithelial cells // *J Periodontol*. 2013. Vol. 84. P. 126—133
20. Пешкова Э.К., 2016; Пешкова Э.К. Морфофункциональная оценка особенностей зубочелюстного комплекса у больных с гипотиреозом и без патологии щитовидной железы: дис. ... канд.мед.наук /Э.К. Пешкова, ФГАОУ ВО «Белгородский государственный национальный исследовательский университет», Белгород, 2016. - 103 с.

БИМЕДИЦИНА ВА АМАЛИЁТ ЖУРНАЛИ

8 ЖИЛД, 4 СОН

ЖУРНАЛ БИМЕДИЦИНЫ И ПРАКТИКИ

ТОМ 8, НОМЕР 4

JOURNAL OF BIOMEDICINE AND PRACTICE

VOLUME 8, ISSUE 4

Контакт редакций журналов. www.tadqiqot.uz
ООО Tadqiqot город Ташкент,
улица Амира Темура пр.1, дом-2.
Web: <http://www.tadqiqot.uz/>; E-mail: info@tadqiqot.uz
Тел: (+998-94) 404-0000

Editorial staff of the journals of www.tadqiqot.uz
Tadqiqot LLC The city of Tashkent,
Amir Temur Street pr.1, House 2.
Web: <http://www.tadqiqot.uz/>; E-mail: info@tadqiqot.uz
Phone: (+998-94) 404-0000